Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$22.04 USD
+0.46 (2.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $22.05 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Tyra Biosciences, Inc. [TYRA]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Data Nears; TYRA-430 Enters Clinic; 2Q24 Results; Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; SURF301 Data Ahead; TYRA-430 Debuts as IND Cleared
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Proof-of-Concept Data Established for TYRA-300 in HCH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Data Have Positive Implications for TYRA-300 in ACH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Crucial TYRA-300 Urothelial Cancer Data in 2H24; 1Q24 Financial Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Data 2H24; 2023 Financials; Adding HCH to Model - Raising PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Rare Pediatric Disease Designation For TYRA-300 Enables Path to PRV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Layering in the PIPE; Favorable Setup into Initial TYRA-300 Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Dose Escalation; 2024 Data; TYRA-200 Dosing Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TYRA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-200 Dosing to Begin by YE23; 3Q23 Financials; Modulating PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M